Disease Domain | Count |
---|---|
Neoplasms | 9 |
Endocrinology and Metabolic Disease | 5 |
Top 5 Drug Type | Count |
---|---|
Fusion protein | 5 |
Nanobody | 2 |
Trispecific antibody | 2 |
Bispecific T-cell Engager (BiTE) | 2 |
Diagnostic radiopharmaceuticals | 1 |
Target |
Mechanism FGF21R agonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PDL1 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GCGR antagonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date16 Aug 2024 |
Sponsor / Collaborator |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Start Date27 Nov 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
DR10624 ( FGF21R x GCGR x GLP-1R ) | Hypertriglyceridemia More | Phase 2 |
DR10628 ( GIPR x GLP-1R ) | Obesity More | Phase 1 |
DR10627 ( GCGR x GIPR x GLP-1R ) | Nonalcoholic Steatohepatitis More | Phase 1 |
DR-30303 ( CLDN18.2 ) | CLDN18.2 positive Solid Tumors More | Phase 1 |
DR-30206 ( PDL1 x TGF-β x VEGF ) | Advanced Malignant Solid Neoplasm More | Phase 1 |